Activity-dependent MAP6 scaffolding at synapses

Target: MAP6 Composite Score: 0.600 Price: $0.51▼5.3% Citation Quality: 55% neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Moderate (55%)
6
Citations
1
Debates
6
Supporting
2
Opposing
Quality Report Card click to collapse
B
Composite: 0.600
Top 44% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.65 Top 46%
B Evidence Strength 15% 0.60 Top 37%
B Novelty 12% 0.60 Top 66%
B Feasibility 12% 0.60 Top 51%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
B+ Reproducibility 5% 0.76 Top 17%
Evidence
6 supporting | 2 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 4 related hypothesis share this target

Description

MAP6 may scaffold signaling complexes at synapses in an activity-dependent manner, linking NMDA receptor activation to cytoskeletal remodeling via its multiple functional domains

Prediction: MAP6 will physically associate with synaptic signaling proteins in a phosphorylation-dependent manner, and LTP-inducing stimulation will recruit MAP6 to dendritic spines

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["MAP6 Occupancy on Microtubules
Cold-Stable Cytoskeletal Support"] B["Tau/MAPT Lattice Competition
Dynamic Binding Balance"] C["Synaptic Remodeling Signals
NMDA-Linked Cytoskeletal Plasticity"] D["Axonal Transport and Branching
Circuit Adaptation"] E["MAP6-Tau Imbalance
Rigid or Unstable Cytoskeleton"] A --> B B --> C C --> D E -.->|"disrupts"| B style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style D fill:#1b5e20,stroke:#81c784,color:#81c784 style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for Q96JE9

View AlphaFold Structure

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for MAP6 from GTEx v10.

Cortex42.4 Frontal Cortex BA941.4 Cerebellum36.7 Hypothalamus35.9 Nucleus accumbens basal ganglia34.4 Cerebellar Hemisphere34.0 Anterior cingulate cortex BA2433.1 Caudate basal ganglia27.9 Spinal cord cervical c-125.5 Amygdala24.3 Hippocampus24.1 Putamen basal ganglia22.3 Substantia nigra18.0median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.65 (15%) Evidence 0.60 (15%) Novelty 0.60 (12%) Feasibility 0.60 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.76 (5%) KG Connect 0.50 (8%) 0.600 composite
8 citations 7 with PMID 7 medium Validation: 0% 6 supporting / 2 opposing
For (6)
5
2
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
3
MECH 3CLIN 2GENE 3EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Cerebellin-neurexin complexes instructing synapse …SupportingMECHCurr Opin Neuro… MEDIUM2023-PMID:37209532-
Sensory neurons drive pancreatic cancer progressio…SupportingGENECancer Cell MEDIUM2025-PMID:41005304-
mTOR-dependent synapse formation underlies the rap…SupportingGENEScience MEDIUM2010-PMID:20724638-
Distinct neurexin-cerebellin complexes control AMP…SupportingMECHElife MEDIUM2022-PMID:36205393-
Beyond NMDA Receptors: Homeostasis at the Glutamat…SupportingCLINInt J Mol Sci MEDIUM2022-PMID:35955750-
Tau/MAP6 antagonism is shown in neuronal developme…OpposingGENEJ Cell Sci MEDIUM2024-PMID:39257379-
A microtubule-stabilizing peptide strategy failed …OpposingCLINLancet Neurol MEDIUM2014-PMID:24873720-
MAP6 may scaffold signaling complexes at synapses …SupportingMECH------
Legacy Card View — expandable citation cards

Supporting Evidence 6

MAP6 may scaffold signaling complexes at synapses in an activity-dependent manner, linking NMDA receptor activ…
MAP6 may scaffold signaling complexes at synapses in an activity-dependent manner, linking NMDA receptor activation to cytoskeletal remodeling via its multiple functional domains
Cerebellin-neurexin complexes instructing synapse properties. MEDIUM
Curr Opin Neurobiol · 2023 · PMID:37209532
Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. MEDIUM
Cancer Cell · 2025 · PMID:41005304
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. MEDIUM
Science · 2010 · PMID:20724638
Distinct neurexin-cerebellin complexes control AMPA- and NMDA-receptor responses in a circuit-dependent manner… MEDIUM
Distinct neurexin-cerebellin complexes control AMPA- and NMDA-receptor responses in a circuit-dependent manner.
Elife · 2022 · PMID:36205393
Beyond NMDA Receptors: Homeostasis at the Glutamate Tripartite Synapse and Its Contributions to Cognitive Dysf… MEDIUM
Beyond NMDA Receptors: Homeostasis at the Glutamate Tripartite Synapse and Its Contributions to Cognitive Dysfunction in Schizophrenia.
Int J Mol Sci · 2022 · PMID:35955750

Opposing Evidence 2

Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance… MEDIUM
Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response.
J Cell Sci · 2024 · PMID:39257379
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, … MEDIUM
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy.
Lancet Neurol · 2014 · PMID:24873720
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

0.520.550.58 0.62 0.48 2026-04-252026-04-262026-04-27 Market PriceScoreevidencedebate 7 events
7d Trend
Falling
7d Momentum
▼ 5.3%
Volatility
High
0.1145
Events (7d)
7

Clinical Trials (1) Relevance: 70%

0
Active
0
Completed
0
Total Enrolled
Untitled Trial Unknown
Unknown ·

📚 Cited Papers (7)

No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
6

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.650

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for MAP6.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAP6 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Tau/MAP6 antagonism in neurodegeneration progression
Score: 0.650 | neurodegeneration
Domain boundary cross-talk hypothesis
Score: 0.600 | neurodegeneration
Tau-Independent Microtubule Stabilization via MAP6 Enhancement
Score: 0.567 | neurodegeneration
MAP6-mediated microtubule stabilization as therapeutic target
Score: 0.500 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
IF neuronal activity is selectively increased via chemogenetic activation of excitatory neurons in cultured hippocampal networks, THEN MAP6 protein will show a significant increase in synaptic spine localization (≥40% increase in spine/cytoplasm ratio) within 60 minutes post-stimulation.
pending conf: 0.65
Expected outcome: Increased MAP6 accumulation at dendritic spines as measured by live-cell imaging of MAP6-GFP expressing neurons
Falsified by: MAP6 spine/cytoplasm ratio changes by <20% or shows no change despite robust neuronal activity increase (c-Fos upregulation ≥3-fold confirms activation)
Method: Dissociated hippocampal neuron cultures from E18 rats, transfected with MAP6-GFP and hM3Dq-mCherry, treated with CNO (10μM) for activity induction, live confocal microscopy time-lapse imaging at 15-min intervals for 90 min
IF MAP6 phosphorylation-deficient knockin mice (S→A mutations at predicted activity-regulated sites) are subjected to theta-burst LTP induction, THEN the maintenance phase of LTP (60-120 min post-induction) will show significantly reduced potentiation compared to wild-type littermates.
pending conf: 0.58
Expected outcome: Reduced LTP maintenance magnitude (≤150% of baseline) at Schaffer collateral-CA1 synapses in knockin vs wild-type mice
Falsified by: LTP maintenance in knockin mice remains within 10% of wild-type magnitude (both ≥160% baseline), indicating MAP6 phosphorylation is not required for LTP
Method: Acute hippocampal brain slices from 8-12 week old male MAP6 phospho-mutant mice and WT controls, field recordings at CA1 stratum radiatum, theta-burst stimulation (4 trains of 100Hz/1s), LTP measured 60-180 min post-induction

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

Predicted Protein Structure

🔮 MAP6 — AlphaFold Prediction Q96JE9 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

MAP6-CRMPS cooperative phosphorylation by GSK3β
Score: 0.70 · MAP6/CRMP2
MAP6-mediated microtubule stabilization as therapeutic target
Score: 0.50 · MAP6
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.